{"gene":"GCSH","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2001,"finding":"GCSH (H-protein gene) spans 13.5 kb, consists of five exons, and maps to chromosome 16q24. The transcription initiation site was determined and potential binding sites for transcriptional factors were found in the 5' upstream region. GCSH mRNA is expressed in all 29 human tissues examined, in contrast to P-protein (GLDC), which is expressed only in a limited number of tissues, suggesting distinct transcriptional regulation of each glycine cleavage system (GCS) constituent.","method":"PAC clone isolation, FISH chromosomal mapping, oligonucleotide-cap method (transcription initiation), dot-blot analysis of tissue expression","journal":"Journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genomic characterization and expression profiling by multiple methods in a single focused study","pmids":["11450847"],"is_preprint":false},{"year":2006,"finding":"Mutations in GLDC and AMT (but not GCSH) were identified as the predominant genetic causes of nonketotic hyperglycinemia (NKH) in a comprehensive screen of 69 families; no GCSH mutations were found. GLDC mutations clustered in exon 19 (cofactor-binding site Lys754). A large GLDC exon 1 deletion of multiple independent origins was found across ethnic groups.","method":"Complete coding-region sequencing of GLDC, AMT, and GCSH in 69 NKH families; haplotype analysis","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — comprehensive mutational screen across large cohort, but negative finding for GCSH specifically; positive results establish pathway membership of GCSH","pmids":["16450403"],"is_preprint":false},{"year":2002,"finding":"Heterozygous mutations in GCSH (and GLDC) were identified in patients with transient neonatal hyperglycinemia, establishing that heterozygous carriers for NKH-associated genes can develop transient glycine elevation, placing GCSH in the glycine cleavage system pathway.","method":"Mutation screening of GLDC, AMT, and GCSH in three transient neonatal hyperglycinemia patients","journal":"Annals of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic variant identification in small cohort, single lab, establishes pathway placement for GCSH","pmids":["12402263"],"is_preprint":false},{"year":2023,"finding":"GCSH (H-protein) has a dual role: (1) participation in the glycine cleavage system (one-carbon/glycine metabolism) and (2) protein lipoylation required for bioenergetic enzymes including pyruvate dehydrogenase (PDH) and 2-ketoglutarate dehydrogenase. Biallelic pathogenic variants in GCSH cause combined deficiency of both mitochondrial activities. Functional studies in patient fibroblasts, GCSH knockdown in COS7 cells and yeast, molecular modeling, and in vitro protein studies demonstrated that most variants produce a hypomorphic effect on both lipoylation and glycine metabolism, whereas some missense variants affect primarily one function.","method":"Functional studies in patient fibroblasts, GCSH knockdown in COS7 cells and yeast, molecular modeling, in vitro protein studies, expression analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (patient fibroblasts, knockdown in two cell systems, in vitro protein studies, molecular modeling) in a single rigorous study establishing dual moonlighting function","pmids":["36190515"],"is_preprint":false},{"year":2018,"finding":"GCSH transcript variant 1 (Tv1, protein-coding) overexpression in breast cancer cells increased cellular vitality primarily by accelerating mitochondrial glycine decarboxylation activity. A shorter antisense-like transcript variant (Tv*) can bind Tv1 RNA; Tv1-Tv* RNA binding and overexpression of Tv* led to decreased metabolic activity, membrane damage, and necrosis, establishing a regulatory axis at the transcript level that controls glycine decarboxylation and cell viability.","method":"Overexpression studies of Tv1 and Tv* transcripts, Tv1-Tv* RNA-binding assay, metabolic activity assays (LDH release, extracellular acidification, mitochondrial glycine decarboxylation activity measurement)","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multiple functional assays in a single lab, direct measurement of mitochondrial glycine decarboxylation activity as readout","pmids":["30337557"],"is_preprint":false},{"year":2025,"finding":"In attenuated Gldc mutant mouse brains, GCSH (mitochondrial lipoyl-transfer protein) protein levels were reduced >5-fold alongside reduced lipoylation of the pyruvate dehydrogenase (PDH) complex, accompanied by activation of astrocyte mitochondrial β-oxidation and neuronal PDH activation. This establishes that GCSH decline contributes to remodeling of mitochondrial energy metabolism in the context of GLDC deficiency.","method":"Mouse model of NKH (attenuated Gldc mutation), Western blotting for GCSH and lipoylation markers, metabolic profiling of brain","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vivo mouse model with protein-level and lipoylation readouts, single preprint study, not yet peer-reviewed","pmids":[],"is_preprint":true},{"year":2026,"finding":"GCSH knockdown in colorectal cancer cells suppressed cuproptosis by downregulating FDX1 protein and reducing intracellular Cu2+ and ROS accumulation. Molecular docking suggested a potential GCSH–FDX1 interaction. GCSH was identified as a downstream effector of the PI3K/AKT pathway, and rescue experiments placed GCSH between PI3K/AKT activation and FDX1-mediated cuproptosis resistance.","method":"shRNA knockdown, flow cytometry, Western blotting, intracellular Cu2+/ROS measurement, molecular docking, rescue experiments, CCK-8/wound healing/Transwell assays","journal":"Functional & integrative genomics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, molecular docking is computational, functional assays support pathway placement but mechanism of GCSH–FDX1 interaction not biochemically validated","pmids":["41591502"],"is_preprint":false},{"year":2026,"finding":"In MASH (metabolic dysfunction-associated steatohepatitis) models, GCSH upregulation enhances glycine catabolism, depleting glycine as a substrate for glutathione (GSH) synthesis and thereby reducing GSH/GSSG ratios. Gcsh knockdown suppressed cuproptosis and ameliorated MASH phenotypes; rescue experiments with the GSH synthesis inhibitor BSO reversed protection from Gcsh knockdown, establishing that GSH is a downstream effector of GCSH in a glycine–GSH–cuproptosis regulatory axis.","method":"shRNA-mediated Gcsh knockdown in primary hepatocytes and HepG2 cells, in vivo HFHC diet mouse model, rescue with exogenous glycine and BSO, cuproptosis marker assessment (DLAT oligomerization, Fe-S cluster proteins), metabolic assays (GSH/GSSG, mitochondrial function)","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods with mechanistic rescue experiments in a single lab","pmids":["42082057"],"is_preprint":false}],"current_model":"GCSH encodes the H-protein (lipoyl carrier) of the mitochondrial glycine cleavage system and functions dually: it scaffolds lipoyl transfer required for lipoylation of pyruvate dehydrogenase and 2-ketoglutarate dehydrogenase, and it participates in glycine decarboxylation/one-carbon metabolism; pathogenic variants impair either or both functions, causing nonketotic hyperglycinemia and/or combined lipoate deficiency, and in metabolic disease contexts GCSH-driven glycine catabolism depletes GSH, sensitizing cells to cuproptosis via FDX1 downregulation."},"narrative":{"mechanistic_narrative":"GCSH encodes the H-protein, a mitochondrial lipoyl-carrier component of the glycine cleavage system that participates in glycine decarboxylation and one-carbon metabolism while also serving as a lipoyl-transfer scaffold required for lipoylation of bioenergetic enzymes including pyruvate dehydrogenase and 2-ketoglutarate dehydrogenase [PMID:36190515]. Unlike the limited tissue expression of the P-protein gene GLDC, GCSH is broadly expressed across human tissues, consistent with a role beyond glycine catabolism alone [PMID:11450847]. Genetic evidence places GCSH within the glycine cleavage pathway, with biallelic pathogenic variants causing combined deficiency of both lipoylation and glycine metabolism—most variants acting as hypomorphs on both functions and certain missense variants affecting predominantly one [PMID:36190515]; heterozygous GCSH variants are associated with transient neonatal hyperglycinemia [PMID:12402263]. The two functions are separable in disease: reduction of GCSH protein in GLDC-deficient brain coincides with diminished PDH lipoylation and remodeling of mitochondrial energy metabolism. In metabolic and oncologic contexts, GCSH-driven glycine catabolism depletes glycine available for glutathione synthesis, lowering the GSH/GSSG ratio and sensitizing cells to copper-dependent cell death (cuproptosis); GCSH acts downstream of PI3K/AKT signaling and is linked to FDX1-mediated cuproptosis regulation [PMID:41591502, PMID:42082057].","teleology":[{"year":2001,"claim":"Established the genomic structure and expression pattern of GCSH, distinguishing its regulation from other glycine cleavage system components and hinting at a broader role.","evidence":"PAC clone isolation, FISH mapping, transcription initiation mapping, and tissue dot-blot expression profiling","pmids":["11450847"],"confidence":"Medium","gaps":["Does not define the functional consequence of broad tissue expression","No protein-level or enzymatic characterization"]},{"year":2002,"claim":"Placed GCSH genetically within the glycine cleavage system by linking heterozygous variants to transient glycine elevation.","evidence":"Mutation screening of GLDC, AMT, and GCSH in three transient neonatal hyperglycinemia patients","pmids":["12402263"],"confidence":"Medium","gaps":["Very small cohort","Heterozygous-variant causality not functionally proven"]},{"year":2006,"claim":"Defined the relative genetic contribution of GCS components to nonketotic hyperglycinemia, with GLDC and AMT dominant and no GCSH coding mutations in the cohort.","evidence":"Complete coding-region sequencing of GLDC, AMT, and GCSH in 69 NKH families with haplotype analysis","pmids":["16450403"],"confidence":"Medium","gaps":["Negative result for GCSH does not exclude rare or non-coding variants","No functional assays for GCSH"]},{"year":2018,"claim":"Identified a transcript-level regulatory axis in which a sense GCSH variant promotes glycine decarboxylation and cell viability while an antisense-like variant counteracts it.","evidence":"Overexpression of Tv1/Tv* transcripts, Tv1-Tv* RNA-binding assay, and metabolic/viability readouts in breast cancer cells","pmids":["30337557"],"confidence":"Medium","gaps":["Mechanism of Tv* RNA action not defined","Single cancer cell context"]},{"year":2023,"claim":"Resolved GCSH as a dual-function (moonlighting) protein required for both glycine metabolism and lipoylation of bioenergetic enzymes, with variant-specific functional effects causing combined deficiency.","evidence":"Patient fibroblasts, GCSH knockdown in COS7 and yeast, molecular modeling, and in vitro protein studies","pmids":["36190515"],"confidence":"High","gaps":["Structural basis for separating the two functions only modeled","Lipoyl-transfer biochemistry not fully reconstituted"]},{"year":2025,"claim":"Showed in vivo that GCSH decline in GLDC deficiency reduces PDH lipoylation and remodels brain mitochondrial energy metabolism, connecting the two GCSH functions in a disease model.","evidence":"Attenuated Gldc mutant mouse brain, Western blotting for GCSH/lipoylation, and metabolic profiling (preprint)","pmids":[],"confidence":"Medium","gaps":["Preprint, not peer-reviewed","Causality of GCSH loss versus secondary GLDC effects not isolated"]},{"year":2026,"claim":"Defined a glycine-GSH-cuproptosis axis in which GCSH-driven glycine catabolism depletes glutathione and modulates copper-dependent cell death, downstream of PI3K/AKT and linked to FDX1.","evidence":"shRNA knockdown in colorectal cancer and hepatocyte/HepG2 cells, HFHC/MASH mouse models, BSO/glycine rescue, cuproptosis markers, and molecular docking","pmids":["41591502","42082057"],"confidence":"Medium","gaps":["GCSH-FDX1 interaction only computational, not biochemically validated","Cuproptosis-resistance role derived from cancer/MASH contexts only"]},{"year":null,"claim":"How the lipoyl-transfer and glycine-decarboxylation activities of GCSH are structurally partitioned and regulated, and whether GCSH directly interacts with FDX1, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No experimentally validated GCSH-FDX1 binding","No reconstituted structural model separating the two functions","Regulation of GCSH abundance across tissues uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[3,4]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[3,5]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,4]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[7]}],"complexes":["glycine cleavage system"],"partners":["FDX1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P23434","full_name":"Glycine cleavage system H protein, mitochondrial","aliases":["Lipoic acid-containing protein"],"length_aa":173,"mass_kda":18.9,"function":"The glycine cleavage system catalyzes the degradation of glycine. The H protein (GCSH) shuttles the methylamine group of glycine from the P protein (GLDC) to the T protein (GCST). Has a pivotal role in the lipoylation of enzymes involved in cellular energetics such as the mitochondrial dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex (DLAT), and the mitochondrial dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex (DLST) (PubMed:36190515)","subcellular_location":"Mitochondrion","url":"https://www.uniprot.org/uniprotkb/P23434/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/GCSH","classification":"Common Essential","n_dependent_lines":572,"n_total_lines":1208,"dependency_fraction":0.4735099337748344},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"IGF2BP3","stoichiometry":0.2},{"gene":"MMGT1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/GCSH","total_profiled":1310},"omim":[{"mim_id":"620423","title":"MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 7; MMDS7","url":"https://www.omim.org/entry/620423"},{"mim_id":"617659","title":"LIPOYL(OCTANOYL) TRANSFERASE 2; LIPT2","url":"https://www.omim.org/entry/617659"},{"mim_id":"616299","title":"LIPOYLTRANSFERASE 1 DEFICIENCY; LIPT1D","url":"https://www.omim.org/entry/616299"},{"mim_id":"610284","title":"LIPOYLTRANSFERASE 1; LIPT1","url":"https://www.omim.org/entry/610284"},{"mim_id":"605899","title":"GLYCINE ENCEPHALOPATHY 1; GCE1","url":"https://www.omim.org/entry/605899"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":134.4}],"url":"https://www.proteinatlas.org/search/GCSH"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P23434","domains":[{"cath_id":"2.40.50.100","chopping":"56-171","consensus_level":"high","plddt":97.3072,"start":56,"end":171}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P23434","model_url":"https://alphafold.ebi.ac.uk/files/AF-P23434-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P23434-F1-predicted_aligned_error_v6.png","plddt_mean":85.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GCSH","jax_strain_url":"https://www.jax.org/strain/search?query=GCSH"},"sequence":{"accession":"P23434","fasta_url":"https://rest.uniprot.org/uniprotkb/P23434.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P23434/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P23434"}},"corpus_meta":[{"pmid":"16450403","id":"PMC_16450403","title":"Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16450403","citation_count":80,"is_preprint":false},{"pmid":"11450847","id":"PMC_11450847","title":"Chromosomal localization, structure, single-nucleotide polymorphisms, and expression of the human H-protein gene of the glycine cleavage system (GCSH), a candidate gene for nonketotic hyperglycinemia.","date":"2001","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11450847","citation_count":31,"is_preprint":false},{"pmid":"11774239","id":"PMC_11774239","title":"Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human colorectal carcinoma.","date":"2002","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11774239","citation_count":25,"is_preprint":false},{"pmid":"30337557","id":"PMC_30337557","title":"GCSH antisense regulation determines breast cancer cells' viability.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30337557","citation_count":22,"is_preprint":false},{"pmid":"12402263","id":"PMC_12402263","title":"Heterozygous GLDC and GCSH gene mutations in transient neonatal hyperglycinemia.","date":"2002","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12402263","citation_count":20,"is_preprint":false},{"pmid":"34204789","id":"PMC_34204789","title":"PLEK2, RRM2, GCSH: A Novel WWOX-Dependent Biomarker Triad of Glioblastoma at the Crossroads of Cytoskeleton Reorganization and Metabolism Alterations.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34204789","citation_count":17,"is_preprint":false},{"pmid":"36190515","id":"PMC_36190515","title":"Pathogenic variants in GCSH encoding the moonlighting H-protein cause combined nonketotic hyperglycinemia and lipoate deficiency.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36190515","citation_count":12,"is_preprint":false},{"pmid":"33890291","id":"PMC_33890291","title":"Biallelic start loss variant, c.1A > G in GCSH is associated with variant nonketotic hyperglycinemia.","date":"2021","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33890291","citation_count":7,"is_preprint":false},{"pmid":"38027603","id":"PMC_38027603","title":"Integrated analysis reveals a potential cuproptosis-related ceRNA axis SNHG17/miR-29a-3p/GCSH in prostate adenocarcinoma.","date":"2023","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/38027603","citation_count":4,"is_preprint":false},{"pmid":"27325422","id":"PMC_27325422","title":"Mutation analysis of GLDC, AMT and GCSH in cataract captive-bred vervet monkeys (Chlorocebus aethiops).","date":"2016","source":"Journal of medical primatology","url":"https://pubmed.ncbi.nlm.nih.gov/27325422","citation_count":4,"is_preprint":false},{"pmid":"41591502","id":"PMC_41591502","title":"GCSH promotes colorectal cancer progression by inhibiting Cuproptosis through the PI3K/AKT-FDX1 axis.","date":"2026","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/41591502","citation_count":0,"is_preprint":false},{"pmid":"42082057","id":"PMC_42082057","title":"GCSH promotes MASH progression by regulating cuproptosis through the glycine-GSH metabolic pathway.","date":"2026","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/42082057","citation_count":0,"is_preprint":false},{"pmid":"42111497","id":"PMC_42111497","title":"Multiomics Characterization of GCSH + Macrophages Reveals Therapeutic Vulnerabilities and Immune-Metabolic Crosstalk in Triple-Negative Breast Cancer.","date":"2026","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/42111497","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.20.25340670","title":"Untargeted 1H NMR-based metabolomics and high-pressure liquid chromatography analysis reveal sexual dimorphism in the serum metabolic profiles of Parkinson’s disease patients harbouring rare genetic variants","date":"2025-11-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.20.25340670","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.30.25339159","title":"Untargeted  <sup>1</sup>  H NMR-based metabolomics reveal sex-based differences in blood metabolome profiles among patients with Parkinson’s disease, regardless of their idiopathic or genetic subtype","date":"2025-11-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.30.25339159","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.12.664515","title":"Variants in glycine decarboxylase activate mechanisms of mitochondrial energy metabolism in the brain","date":"2025-07-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.12.664515","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10822,"output_tokens":2352,"usd":0.033873,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9562,"output_tokens":2533,"usd":0.055567,"stage2_stop_reason":"end_turn"},"total_usd":0.08944,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"GCSH (H-protein gene) spans 13.5 kb, consists of five exons, and maps to chromosome 16q24. The transcription initiation site was determined and potential binding sites for transcriptional factors were found in the 5' upstream region. GCSH mRNA is expressed in all 29 human tissues examined, in contrast to P-protein (GLDC), which is expressed only in a limited number of tissues, suggesting distinct transcriptional regulation of each glycine cleavage system (GCS) constituent.\",\n      \"method\": \"PAC clone isolation, FISH chromosomal mapping, oligonucleotide-cap method (transcription initiation), dot-blot analysis of tissue expression\",\n      \"journal\": \"Journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genomic characterization and expression profiling by multiple methods in a single focused study\",\n      \"pmids\": [\"11450847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Mutations in GLDC and AMT (but not GCSH) were identified as the predominant genetic causes of nonketotic hyperglycinemia (NKH) in a comprehensive screen of 69 families; no GCSH mutations were found. GLDC mutations clustered in exon 19 (cofactor-binding site Lys754). A large GLDC exon 1 deletion of multiple independent origins was found across ethnic groups.\",\n      \"method\": \"Complete coding-region sequencing of GLDC, AMT, and GCSH in 69 NKH families; haplotype analysis\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — comprehensive mutational screen across large cohort, but negative finding for GCSH specifically; positive results establish pathway membership of GCSH\",\n      \"pmids\": [\"16450403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Heterozygous mutations in GCSH (and GLDC) were identified in patients with transient neonatal hyperglycinemia, establishing that heterozygous carriers for NKH-associated genes can develop transient glycine elevation, placing GCSH in the glycine cleavage system pathway.\",\n      \"method\": \"Mutation screening of GLDC, AMT, and GCSH in three transient neonatal hyperglycinemia patients\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic variant identification in small cohort, single lab, establishes pathway placement for GCSH\",\n      \"pmids\": [\"12402263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GCSH (H-protein) has a dual role: (1) participation in the glycine cleavage system (one-carbon/glycine metabolism) and (2) protein lipoylation required for bioenergetic enzymes including pyruvate dehydrogenase (PDH) and 2-ketoglutarate dehydrogenase. Biallelic pathogenic variants in GCSH cause combined deficiency of both mitochondrial activities. Functional studies in patient fibroblasts, GCSH knockdown in COS7 cells and yeast, molecular modeling, and in vitro protein studies demonstrated that most variants produce a hypomorphic effect on both lipoylation and glycine metabolism, whereas some missense variants affect primarily one function.\",\n      \"method\": \"Functional studies in patient fibroblasts, GCSH knockdown in COS7 cells and yeast, molecular modeling, in vitro protein studies, expression analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (patient fibroblasts, knockdown in two cell systems, in vitro protein studies, molecular modeling) in a single rigorous study establishing dual moonlighting function\",\n      \"pmids\": [\"36190515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GCSH transcript variant 1 (Tv1, protein-coding) overexpression in breast cancer cells increased cellular vitality primarily by accelerating mitochondrial glycine decarboxylation activity. A shorter antisense-like transcript variant (Tv*) can bind Tv1 RNA; Tv1-Tv* RNA binding and overexpression of Tv* led to decreased metabolic activity, membrane damage, and necrosis, establishing a regulatory axis at the transcript level that controls glycine decarboxylation and cell viability.\",\n      \"method\": \"Overexpression studies of Tv1 and Tv* transcripts, Tv1-Tv* RNA-binding assay, metabolic activity assays (LDH release, extracellular acidification, mitochondrial glycine decarboxylation activity measurement)\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multiple functional assays in a single lab, direct measurement of mitochondrial glycine decarboxylation activity as readout\",\n      \"pmids\": [\"30337557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In attenuated Gldc mutant mouse brains, GCSH (mitochondrial lipoyl-transfer protein) protein levels were reduced >5-fold alongside reduced lipoylation of the pyruvate dehydrogenase (PDH) complex, accompanied by activation of astrocyte mitochondrial β-oxidation and neuronal PDH activation. This establishes that GCSH decline contributes to remodeling of mitochondrial energy metabolism in the context of GLDC deficiency.\",\n      \"method\": \"Mouse model of NKH (attenuated Gldc mutation), Western blotting for GCSH and lipoylation markers, metabolic profiling of brain\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vivo mouse model with protein-level and lipoylation readouts, single preprint study, not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"GCSH knockdown in colorectal cancer cells suppressed cuproptosis by downregulating FDX1 protein and reducing intracellular Cu2+ and ROS accumulation. Molecular docking suggested a potential GCSH–FDX1 interaction. GCSH was identified as a downstream effector of the PI3K/AKT pathway, and rescue experiments placed GCSH between PI3K/AKT activation and FDX1-mediated cuproptosis resistance.\",\n      \"method\": \"shRNA knockdown, flow cytometry, Western blotting, intracellular Cu2+/ROS measurement, molecular docking, rescue experiments, CCK-8/wound healing/Transwell assays\",\n      \"journal\": \"Functional & integrative genomics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, molecular docking is computational, functional assays support pathway placement but mechanism of GCSH–FDX1 interaction not biochemically validated\",\n      \"pmids\": [\"41591502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"In MASH (metabolic dysfunction-associated steatohepatitis) models, GCSH upregulation enhances glycine catabolism, depleting glycine as a substrate for glutathione (GSH) synthesis and thereby reducing GSH/GSSG ratios. Gcsh knockdown suppressed cuproptosis and ameliorated MASH phenotypes; rescue experiments with the GSH synthesis inhibitor BSO reversed protection from Gcsh knockdown, establishing that GSH is a downstream effector of GCSH in a glycine–GSH–cuproptosis regulatory axis.\",\n      \"method\": \"shRNA-mediated Gcsh knockdown in primary hepatocytes and HepG2 cells, in vivo HFHC diet mouse model, rescue with exogenous glycine and BSO, cuproptosis marker assessment (DLAT oligomerization, Fe-S cluster proteins), metabolic assays (GSH/GSSG, mitochondrial function)\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods with mechanistic rescue experiments in a single lab\",\n      \"pmids\": [\"42082057\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GCSH encodes the H-protein (lipoyl carrier) of the mitochondrial glycine cleavage system and functions dually: it scaffolds lipoyl transfer required for lipoylation of pyruvate dehydrogenase and 2-ketoglutarate dehydrogenase, and it participates in glycine decarboxylation/one-carbon metabolism; pathogenic variants impair either or both functions, causing nonketotic hyperglycinemia and/or combined lipoate deficiency, and in metabolic disease contexts GCSH-driven glycine catabolism depletes GSH, sensitizing cells to cuproptosis via FDX1 downregulation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GCSH encodes the H-protein, a mitochondrial lipoyl-carrier component of the glycine cleavage system that participates in glycine decarboxylation and one-carbon metabolism while also serving as a lipoyl-transfer scaffold required for lipoylation of bioenergetic enzymes including pyruvate dehydrogenase and 2-ketoglutarate dehydrogenase [#3]. Unlike the limited tissue expression of the P-protein gene GLDC, GCSH is broadly expressed across human tissues, consistent with a role beyond glycine catabolism alone [#0]. Genetic evidence places GCSH within the glycine cleavage pathway, with biallelic pathogenic variants causing combined deficiency of both lipoylation and glycine metabolism—most variants acting as hypomorphs on both functions and certain missense variants affecting predominantly one [#3]; heterozygous GCSH variants are associated with transient neonatal hyperglycinemia [#2]. The two functions are separable in disease: reduction of GCSH protein in GLDC-deficient brain coincides with diminished PDH lipoylation and remodeling of mitochondrial energy metabolism [#5]. In metabolic and oncologic contexts, GCSH-driven glycine catabolism depletes glycine available for glutathione synthesis, lowering the GSH/GSSG ratio and sensitizing cells to copper-dependent cell death (cuproptosis); GCSH acts downstream of PI3K/AKT signaling and is linked to FDX1-mediated cuproptosis regulation [#6, #7].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established the genomic structure and expression pattern of GCSH, distinguishing its regulation from other glycine cleavage system components and hinting at a broader role.\",\n      \"evidence\": \"PAC clone isolation, FISH mapping, transcription initiation mapping, and tissue dot-blot expression profiling\",\n      \"pmids\": [\"11450847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not define the functional consequence of broad tissue expression\", \"No protein-level or enzymatic characterization\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Placed GCSH genetically within the glycine cleavage system by linking heterozygous variants to transient glycine elevation.\",\n      \"evidence\": \"Mutation screening of GLDC, AMT, and GCSH in three transient neonatal hyperglycinemia patients\",\n      \"pmids\": [\"12402263\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Very small cohort\", \"Heterozygous-variant causality not functionally proven\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the relative genetic contribution of GCS components to nonketotic hyperglycinemia, with GLDC and AMT dominant and no GCSH coding mutations in the cohort.\",\n      \"evidence\": \"Complete coding-region sequencing of GLDC, AMT, and GCSH in 69 NKH families with haplotype analysis\",\n      \"pmids\": [\"16450403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Negative result for GCSH does not exclude rare or non-coding variants\", \"No functional assays for GCSH\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified a transcript-level regulatory axis in which a sense GCSH variant promotes glycine decarboxylation and cell viability while an antisense-like variant counteracts it.\",\n      \"evidence\": \"Overexpression of Tv1/Tv* transcripts, Tv1-Tv* RNA-binding assay, and metabolic/viability readouts in breast cancer cells\",\n      \"pmids\": [\"30337557\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of Tv* RNA action not defined\", \"Single cancer cell context\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved GCSH as a dual-function (moonlighting) protein required for both glycine metabolism and lipoylation of bioenergetic enzymes, with variant-specific functional effects causing combined deficiency.\",\n      \"evidence\": \"Patient fibroblasts, GCSH knockdown in COS7 and yeast, molecular modeling, and in vitro protein studies\",\n      \"pmids\": [\"36190515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for separating the two functions only modeled\", \"Lipoyl-transfer biochemistry not fully reconstituted\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed in vivo that GCSH decline in GLDC deficiency reduces PDH lipoylation and remodels brain mitochondrial energy metabolism, connecting the two GCSH functions in a disease model.\",\n      \"evidence\": \"Attenuated Gldc mutant mouse brain, Western blotting for GCSH/lipoylation, and metabolic profiling (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not peer-reviewed\", \"Causality of GCSH loss versus secondary GLDC effects not isolated\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined a glycine-GSH-cuproptosis axis in which GCSH-driven glycine catabolism depletes glutathione and modulates copper-dependent cell death, downstream of PI3K/AKT and linked to FDX1.\",\n      \"evidence\": \"shRNA knockdown in colorectal cancer and hepatocyte/HepG2 cells, HFHC/MASH mouse models, BSO/glycine rescue, cuproptosis markers, and molecular docking\",\n      \"pmids\": [\"41591502\", \"42082057\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GCSH-FDX1 interaction only computational, not biochemically validated\", \"Cuproptosis-resistance role derived from cancer/MASH contexts only\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the lipoyl-transfer and glycine-decarboxylation activities of GCSH are structurally partitioned and regulated, and whether GCSH directly interacts with FDX1, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimentally validated GCSH-FDX1 binding\", \"No reconstituted structural model separating the two functions\", \"Regulation of GCSH abundance across tissues uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [3, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [3, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 4]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [\"glycine cleavage system\"],\n    \"partners\": [\"FDX1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":4,"faith_total":4,"faith_pct":100.0}}